Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| Rush University Medical Center | OTHER |
| University of California, San Francisco | OTHER |
| amfAR, The Foundation for AIDS Research | OTHER |
Not provided
Not provided
Not provided
Not provided
Not provided
This observational study will prospectively characterize the long-term symptoms and side effects of COVID-19 in cohorts of people living with and without HIV. This will be achieved through a series of remote study visits involving completing surveys about health history, symptoms, mood, quality of life and changes in health, and up to two blood draws from home through the use of a mobile phlebotomy service.
This is a prospective observational study being conducted to learn about late (2+ weeks or more) effects of COVID-19 in people living with and without HIV. The investigators plan to do this by studying people who have COVID-19 and people who have not had COVID-19, and by studying people living with HIV and people who are HIV-negative. The investigators will investigate the average duration of symptoms after COVID-19, how these symptoms affect quality of life, and what medical complications are common after COVID-19 in people with and without HIV.
Participation involves:
This is a fully remote study and all study activities can be done from home or another location of the participant's choosing.
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| HIV+ adults with recent COVID-19 diagnosis | Required study visits:
Optional study visits: • Follow up questionnaire at month 2, month 6, and month 12 |
| |
| HIV- adults with recent COVID-19 diagnosis | Required study visits:
Optional study visits: • Follow up questionnaire at month 2, month 6, and month 12 |
| |
| HIV+ adults with no history of COVID-19 | Required study visits:
Optional study visits: • Follow up questionnaire at 1, 5, and 11 months after first follow up questionnaire. |
| |
| HIV- adults with no history of COVID-19 | Required study visits:
Optional study visits: • Follow up questionnaire at 1, 5, and 11 months after first follow up questionnaire. |
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| No intervention | Other | (observational study) |
|
| Measure | Description | Time Frame |
|---|---|---|
| Change in symptom severity after COVID-19 infection over 12 months after infection | Time to return to usual health and activities, as measured using the Influenza Patient-reported Outcome (Flu-PRO) instrument. The overall score is calculated as the mean across 32 items, and ranges from 0 (symptom free) to 4 (very severe symptoms). | 1, 2, 4, 6 and 12 months |
| Change in fatigue severity | Presence/absence of fatigue post-symptom onset, severity of fatigue and its effect on activity level as measured using the Fatigue Severity Scale. The Fatigue Severity Scale is a 9-item tool and each item is ranked from 1 (strongly disagree) to 7 (strongly agree). The item scores are added to generate the overall score, ranging from 9 (least severe) to 63 (most severe). | 1 and 4 months |
| Change in number of COVID-19 symptoms experienced over 12 months after infection | Number of symptoms experienced using Flu-PRO and additional COVID-19 specific symptoms in domains of neuropsychiatry, cardiovascular, and skin. Flu-PRO scores range from 0 (symptom free) to 4 (very severe symptoms). | 1, 2, 4, 6 and 12 months |
| Measure | Description | Time Frame |
|---|---|---|
| Change in mMRC rates of dyspnea | The Modified Medical Research Council (mMRC) instrument will be used to measure dyspnea. The mMRC rates severity of dyspnea on a scale of 0 to 4, 4 indicating the highest level of dyspnea severity. | 1 and 4 months |
| Change in cognitive function (learning and memory) as measured by the RAVLT from month 1 to month 4 |
| Measure | Description | Time Frame |
|---|---|---|
| New self-reported diagnoses over 12 months after COVID-19 infection | New medical diagnoses after COVID-19 infection. | 1, 2, 4, 6 and 12 months |
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Investigators will recruit volunteers with and without HIV and with and without a COVID-19 diagnosis from across the contiguous 48 US states in the following numbers:
Investigators aim to enroll a population of PWH that is roughly representative of the demographic and geographic diversity of PWH across the United States.
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Annie Antar, MD,PhD | Infectious Disease - Broadway | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Johns Hopkins University | Baltimore | Maryland | 21287 | United States |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D000086382 | COVID-19 |
| D000094024 | Post-Acute COVID-19 Syndrome |
| ID | Term |
|---|---|
| D011024 | Pneumonia, Viral |
| D011014 | Pneumonia |
| D012141 | Respiratory Tract Infections |
| D007239 | Infections |
Not provided
Not provided
Not provided
Not provided
Not provided
A mobile phlebotomist will draw blood at the participant's home at their convenience. The mobile phlebotomist will overnight ship blood samples using International Air Transport Association (IATA) approved procedures to the Immunology Specialty Lab at Rush University for processing, clinical laboratory testing, and storage. Work with samples will occur at Rush, Johns Hopkins and University of California, San Francisco (UCSF).
Learning and memory assessed through the Rey Auditory Verbal Learning Test (RAVLT), in which participants receive a total learning score (range 0-36), a delayed recall score (range 0-12) and a recognition score (range -12 - +12). In all cases, a higher score indicates better recall. |
| 1 and 4 months |
| Change in cognitive function (attention and executive function) as assessed through oral trail tests from month 1 to month 4 | Attention and executive function assessed through an oral trail test, in which participants are timed between 0 and 300 seconds. A higher time indicates lower attention and executive function. | 1 and 4 months |
| Change in cognitive function (attention and working memory) as assessed through digit span tests from month 1 to month 4 | Attention and working memory assessed through a digit span task-forward and backward test. The forward test is scored from 0-16 and the backward test from 0-18, higher scores indicating better attention and memory. | 1 and 4 months |
| Change in cognitive function (phonemic and semantic fluency) as assessed through letter and category-guided fluency tests from month 1 to month 4 | Phonemic and semantic fluency assessed through a letter-guided and category-guided fluency test. Scores range from 0-100, with a higher score indicating increased fluency. | 1 and 4 months |
| Dysautonomia measured through orthostatic hypotension and orthostatic tachycardia | Orthostatic hypotension and orthostatic tachycardia (decrease in systolic blood pressure of 20 mmHg or decrease in diastolic blood pressure of 10 mmHg after 3 minutes of standing compared to sitting). | 1 month |
| Dysautonomia measured through orthostatic hypotension and orthostatic tachycardia | Orthostatic hypotension and orthostatic tachycardia (decrease in systolic blood pressure of 20 mmHg or decrease in diastolic blood pressure of 10 mmHg after 3 minutes of standing compared to sitting). | 4 months |
| Change in PHQ-9 depression symptoms | Self-reported measure of depressive symptoms using The Patient Health Questionnaire (PHQ-9). The PHQ-9 is a 9 item scale with a score range of 1-27 with higher scores indicating severe depression. | 1 and 4 months |
| Change in quality of life as assessed using the Short Form-36 | Quality of life in the domains of vitality, physical functioning, bodily pain, general health perceptions, physical and emotional and social role functioning, as assessed using the Short Form-36. The Short Form-36 measures physical and mental health using 8 scales. The final score ranges from 0 (worse health status) to 100 (better health status). | 1 and 4 months |
| Change in insomnia as assessed using the Insomnia Severity Index from month 1 to month 4 | Presence, severity, and patterns of insomnia, and its interference with daily functioning as assessed by the Insomnia Severity Index. The Insomnia Severity Index is a 7 item scale with a score range of 0-28. A higher score indicates severe insomnia. | 1 and 4 months |
| Change in anxiety as assessed using the GAD-7 from month 1 to month 4 | Self-reported measure of anxiety using The Generalized Anxiety Disorder (GAD-7). The GAD-7 is a 7 item instrument used to measure or assess anxiety disorders. The score range is from 0-21. A higher score indicates severe anxiety. | 1 and 4 months |
| Change in overall mental health as assessed using the CAT-MH from month 1 to month 4 | Self-reported measures of mental health symptoms (anxiety and depression) using the Computer Adaptive Test-Mental Health (CAT-MH). Scores range from 0-100, with a higher score indicating more severe symptoms. | 1 and 4 months |
| D014777 |
| Virus Diseases |
| D018352 | Coronavirus Infections |
| D003333 | Coronaviridae Infections |
| D030341 | Nidovirales Infections |
| D012327 | RNA Virus Infections |
| D008171 | Lung Diseases |
| D012140 | Respiratory Tract Diseases |
| D000094025 | Post-Infectious Disorders |
| D002908 | Chronic Disease |
| D020969 | Disease Attributes |
| D010335 | Pathologic Processes |
| D013568 | Pathological Conditions, Signs and Symptoms |